XBiotech Inc XBIT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-04-15 |
| Shares Out. | 30,490,000 |
| Website | xbiotech.com/ ↗ |
| Phone | 15123862900 |
| Employees | 87 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$6.7M |
| Free Cash Flow | -$40.8M |
| Total Assets | $133.7M |
| Total Liabilities | $5.2M |
| Equity | $128.5M |
About XBiotech Inc
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
XBiotech Inc is a publicly traded company under the ticker symbol XBIT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2021-12-01)